DE2654119A1 - Pharmazeutisches mittel mit cerebral- vasodilatatorischer wirkung und verfahren zu dessen herstellung - Google Patents
Pharmazeutisches mittel mit cerebral- vasodilatatorischer wirkung und verfahren zu dessen herstellungInfo
- Publication number
- DE2654119A1 DE2654119A1 DE19762654119 DE2654119A DE2654119A1 DE 2654119 A1 DE2654119 A1 DE 2654119A1 DE 19762654119 DE19762654119 DE 19762654119 DE 2654119 A DE2654119 A DE 2654119A DE 2654119 A1 DE2654119 A1 DE 2654119A1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical agent
- agent according
- dispersant
- active compound
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000002490 cerebral effect Effects 0.000 title claims description 11
- 238000000034 method Methods 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title description 3
- 230000000304 vasodilatating effect Effects 0.000 title description 3
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 27
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 claims description 26
- 239000002270 dispersing agent Substances 0.000 claims description 21
- 239000008177 pharmaceutical agent Substances 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 17
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 claims description 13
- 229960002726 vincamine Drugs 0.000 claims description 13
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims description 8
- HONLKDDLTAZVQV-UHFFFAOYSA-N eburnamine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)N5C2=C1 HONLKDDLTAZVQV-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- HONLKDDLTAZVQV-UHOSZYNNSA-N vincanol Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@H](O)N5C2=C1 HONLKDDLTAZVQV-UHOSZYNNSA-N 0.000 claims description 6
- 229950002496 vincanol Drugs 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229940124549 vasodilator Drugs 0.000 claims description 4
- 239000003071 vasodilator agent Substances 0.000 claims description 4
- YCXHPBHFOLIYEB-AABGKKOBSA-N vincaminol Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(CO)N5C2=C1 YCXHPBHFOLIYEB-AABGKKOBSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- ZFCQLDAGNBFMJQ-QUCCMNQESA-N apovincaminic acid Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(O)=O)N5C2=C1 ZFCQLDAGNBFMJQ-QUCCMNQESA-N 0.000 claims description 3
- BOAFIDYFQWIRTC-QFUCXCTJSA-N deoxyvincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@H](C(=O)OC)N5C2=C1 BOAFIDYFQWIRTC-QFUCXCTJSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- VXEGSRKPIUDPQT-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]aniline Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 VXEGSRKPIUDPQT-UHFFFAOYSA-N 0.000 claims description 2
- 239000005049 silicon tetrachloride Substances 0.000 claims description 2
- OZDNDGXASTWERN-CTNGQTDRSA-N Apovincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OC)N5C2=C1 OZDNDGXASTWERN-CTNGQTDRSA-N 0.000 claims 1
- 229950006936 apovincamine Drugs 0.000 claims 1
- OZDNDGXASTWERN-UHFFFAOYSA-N apovincamine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)C=C(C(=O)OC)N5C2=C1 OZDNDGXASTWERN-UHFFFAOYSA-N 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical class O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011164 primary particle Substances 0.000 description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 206010059150 Cerebrosclerosis Diseases 0.000 description 1
- 206010008589 Choking Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- UXMCFEBDJVHVNH-HOJAQTOUSA-N ac1l52id Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(O)=O)N5C2=C1 UXMCFEBDJVHVNH-HOJAQTOUSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- -1 apovincaminic Chemical compound 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005792 cardiovascular activity Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7536733A FR2333507A1 (fr) | 1975-12-01 | 1975-12-01 | Medicament a base de substances possedant le squelette de l'eburnane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2654119A1 true DE2654119A1 (de) | 1977-06-08 |
Family
ID=9163155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762654119 Ceased DE2654119A1 (de) | 1975-12-01 | 1976-11-29 | Pharmazeutisches mittel mit cerebral- vasodilatatorischer wirkung und verfahren zu dessen herstellung |
Country Status (9)
| Country | Link |
|---|---|
| BE (1) | BE848782A (enExample) |
| DE (1) | DE2654119A1 (enExample) |
| DK (1) | DK537476A (enExample) |
| ES (1) | ES453689A1 (enExample) |
| FR (1) | FR2333507A1 (enExample) |
| GB (1) | GB1564035A (enExample) |
| IE (1) | IE44187B1 (enExample) |
| LU (1) | LU76290A1 (enExample) |
| NL (1) | NL7613354A (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2477875A1 (fr) * | 1979-12-10 | 1981-09-18 | Grimberg Georges | Nouveaux produits a base de vincamine |
| IT1209276B (it) * | 1980-11-05 | 1989-07-16 | Magis Farmaceutici | Composizione farmaceutica per la somministrazione orale del metilestere dell'acido 13a-etil-2,3,5,6,12,13,13a,13b-ottaidro-12-idrossi1h-indolo-[3,2,1-de] pirido [3,2,1-ij] [1,5] naftiridina -12-carbossilico |
-
1975
- 1975-12-01 FR FR7536733A patent/FR2333507A1/fr active Granted
-
1976
- 1976-11-25 IE IE258976A patent/IE44187B1/en unknown
- 1976-11-26 BE BE172728A patent/BE848782A/xx not_active IP Right Cessation
- 1976-11-26 ES ES453689A patent/ES453689A1/es not_active Expired
- 1976-11-29 DE DE19762654119 patent/DE2654119A1/de not_active Ceased
- 1976-11-30 LU LU76290A patent/LU76290A1/xx unknown
- 1976-11-30 DK DK537476A patent/DK537476A/da not_active Application Discontinuation
- 1976-12-01 GB GB5016376A patent/GB1564035A/en not_active Expired
- 1976-12-01 NL NL7613354A patent/NL7613354A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NL7613354A (nl) | 1977-06-03 |
| DK537476A (da) | 1977-06-02 |
| ES453689A1 (es) | 1978-03-16 |
| IE44187B1 (en) | 1981-09-09 |
| FR2333507A1 (fr) | 1977-07-01 |
| GB1564035A (en) | 1980-04-02 |
| BE848782A (fr) | 1977-05-26 |
| IE44187L (en) | 1977-06-01 |
| LU76290A1 (enExample) | 1977-05-20 |
| FR2333507B1 (enExample) | 1979-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0178436B1 (de) | Ibuprofen enthaltende Weichgelatinekapseln und Verfahren zu ihrer Herstellung | |
| DE3224619C2 (enExample) | ||
| DE3850434T2 (de) | Arzneimittel, diätetisches Produkt und hygienisches Produkt in Form einer pulverigen Zusammensetzung, erhalten durch Adsorption der Wirkstoffe auf einem schnellöslichen Zucker und Verfahren zur Herstellung dieser Zusammensetzung. | |
| DE3877331T2 (de) | Exifon und ein wasserloesliches polymer enthaltende pharmazeutische zubereitung. | |
| WO1987003480A2 (en) | Medicament with anti-tumoral action containing hexadecylphosphocholine | |
| EP0796103B1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
| DE3537656C2 (enExample) | ||
| DE68906765T2 (de) | Zusammensetzung mit einem extrakt,das durch extraktion mit einem wasserhaltigen organischen loesungsmittel erhalten wurde und verfahren zu seiner herstellung. | |
| EP1509207A1 (de) | Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung | |
| DE3603564A1 (de) | Pharmazeutische praeparate mit analgetrischer wirksamkeit, sowie deren herstellung und verwendung | |
| DD144719A5 (de) | Verfahren zur gewinnung einer natuerlichen polarfraktion mit antipsoriatischer wirksamkeit | |
| CH683824A5 (de) | Zusammensetzung als Mittel zur Behandlung von Entzündungen. | |
| EP1239862B3 (de) | Pharmazeutische zubereitung enthaltend zytostatika und elektronenakzeptoren zur behandlung von krebs | |
| EP0871437B1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
| DE3638124C2 (de) | Neue pharmazeutische Verwendung von Ebselen | |
| EP0618797B1 (de) | Bilobalid enthaltende pharmazeutische zubereitungen zur behandlung von spannungs- und angstzuständen | |
| EP0198172B1 (de) | Pharmazeutische Zubereitung | |
| DE4028945A1 (de) | Kawa-kawa-extrakt, verfahren zu seiner herstellung und seine verwendung | |
| DE60128801T2 (de) | Isoflavone gegen strahlungsinduzierte Sterblichkeit | |
| DE2654119A1 (de) | Pharmazeutisches mittel mit cerebral- vasodilatatorischer wirkung und verfahren zu dessen herstellung | |
| EP0240874B1 (de) | Hochresorbierbare Zubereitungsform des Hymecromons und Verfahren zur Herstellung derselben | |
| DE69301360T2 (de) | Neuroprotektivum | |
| DE69307197T2 (de) | Verwendung von 24,25-Dihydroxyvitamin-D3 zur Herstellung eines Arzneimittel zur Behandlung der Rachitis | |
| DE2625220A1 (de) | Arzneipraeparate mit einem gehalt an 1,3-dithiaverbindungen | |
| EP2229168A1 (de) | Pharmazeutische zusammensetzung zur behandlung von malaria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: BARTELS, H. HELD, M., DIPL.-ING. DR.-ING., PAT.-AN |
|
| 8131 | Rejection |